GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (NAS:OPT) » Definitions » Gross Margin %

Opthea (Opthea) Gross Margin % : -144.26% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Opthea Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Opthea's Gross Profit for the six months ended in Dec. 2023 was $-0.09 Mil. Opthea's Revenue for the six months ended in Dec. 2023 was $0.06 Mil. Therefore, Opthea's Gross Margin % for the quarter that ended in Dec. 2023 was -144.26%.


The historical rank and industry rank for Opthea's Gross Margin % or its related term are showing as below:

OPT' s Gross Margin % Range Over the Past 10 Years
Min: -523.33   Med: -77.52   Max: -53.42
Current: -100


During the past 13 years, the highest Gross Margin % of Opthea was -53.42%. The lowest was -523.33%. And the median was -77.52%.

OPT's Gross Margin % is ranked worse than
95.93% of 738 companies
in the Biotechnology industry
Industry Median: 59.44 vs OPT: -100.00

Opthea had a gross margin of -144.26% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Opthea was 0.00% per year.


Opthea Gross Margin % Historical Data

The historical data trend for Opthea's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Gross Margin % Chart

Opthea Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.21 -377.97 -521.74 -76.92 -53.70

Opthea Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.78 -169.57 -57.69 -51.79 -144.26

Competitive Comparison of Opthea's Gross Margin %

For the Biotechnology subindustry, Opthea's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opthea's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Opthea's Gross Margin % falls into.



Opthea Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Opthea's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-0.1 / 0.108
=(Revenue - Cost of Goods Sold) / Revenue
=(0.108 - 0.166) / 0.108
=-53.70 %

Opthea's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.1 / 0.061
=(Revenue - Cost of Goods Sold) / Revenue
=(0.061 - 0.149) / 0.061
=-144.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Opthea  (NAS:OPT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Opthea had a gross margin of -144.26% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Opthea Gross Margin % Related Terms

Thank you for viewing the detailed overview of Opthea's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea (Opthea) Business Description

Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Opthea (Opthea) Headlines

From GuruFocus

Opthea To Present at SVB Leerink Global Biopharma Conference

By Stock market mentor Stock market mentor 02-06-2023

Opthea Presentation at The Retina World Congress 2022

By GuruFocusNews GuruFocusNews 07-09-2022

Opthea To Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-30-2022

Opthea To Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-10-2022

Opthea To Present at the JMP Securities Life Sciences Conference

By sperokesalga sperokesalga 05-08-2023

Top 5 2nd Quarter Trades of Regal Partners Ltd

By GuruFocus Research GuruFocus Editor 09-09-2022